Enzon Pharmaceuticals, Inc. (ENZN) said Thursday it filed a Form 10 Registration Statement with the U.S. Securities and Exchange Commission related to its plan to spin-off its biotechnology business to Enzon's shareholders.
Earlier in May 2008, Enzon announced its plan to spin-off its biotechnology business, named Evivrus, Inc., to create a separate, publicly-traded, highly-focused biotechnology company.
Evivrus will focus on the discovery and development of important medicines for patients with cancer and other life-threatening conditions utilizing cutting-edge technologies, including PEGylation Customized Linker Technology and Locked Nucleic Acid technology.
For comments and feedback: editorial@rttnews.com